Find Funding Opportunities

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for a limited competition Funding Opportunity Announcement (FOA) utilizing a Cooperative Agreement (U10) to provide continuing support for Clinical Sites in the NIH Exploratory Trials in Parkinson's Disease network (NET-PD). The goal of this initiative is to support completion of NET-PD's current ongoing clinical trials.

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for a limited competition Funding Opportunity Announcement (FOA) utilizing a Cooperative Agreement (U01) to provide continuing support for Clinical and Data Coordinating Centers in the NIH Exploratory Trials in Parkinson's Disease network (NET-PD). The goal of this initiative is to support completion of NET-PD's current ongoing clinical trials.

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health, encourages applications that will develop novel technologies and/or tools to facilitate the study of genes and proteins at the synapse on a large scale. Being able to characterize the synaptome in the context of hundreds of genes/proteins would be a major advance for basic and translational research. The technologies/tools created would be expected to affect the fields of neurology, psychiatry, and neuroscience by enriching existing resources as well as those in development. The new tools should enable discovery science related to the synapse by providing for substantially greater sensitivity, selectivity, spatiotemporal resolution and markedly decreased costs compared to currently available technologies.

The purpose of this FOA is to encourage applications for the Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV-associated Infections in Adults. The Leadership Group (LG) will have overall responsibility for developing, implementing and adapting the networks clinical research agenda to address NIAIDs HIV/AIDS scientific priorities described below (Part 2, Section I, #3). Applications for the LG must be comprised of three separate linked UM1 applications: a Leadership and Operations Center (LOC), a Laboratory Center (LC) and a Statistical and Data Management Center (SDMC).

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences supports broad and fundamental research training in the neurosciences via institutional NRSA research training grants (T32) at domestic institutions of higher education. Trainees appointed to this training grant are financially supported for either one or two years, during the first 2 years of their graduate research training. The primary objective is to prepare individuals for careers in neuroscience that have a significant impact on the health-related research needs of the Nation.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevention CIPN.

NINDS invites new and competing renewal applications for Center Core Grants that provide resources and facilities shared by a minimum of six NINDS-supported investigators. The proposed Centers will offer services and expertise that would be difficult or impractical to support in individual labs. The Centers are expected to capitalize on economies and synergies associated with shared resources, and to foster a collaborative environment among neuroscientists at host institutions.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevention CIPN.

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that seek additional funding to support exploratory clinical trials for projects that were previously funded by NIH STTR Phase II awards. The trials must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of STTR Phase II projects to the commercialization stage by promoting partnerships between NIHs STTR awardees and third-party investors and/or strategic partners.